Pooled analysis of combination antiemetic therapy for chemotherapy-induced nausea and vomiting in patients with colorectal cancer treated with oxaliplatin-based chemotherapy of moderate emetic risk.

BMC Cancer · 2021 · PMC8520642 · PMID 34656107

Europe PMC DOI

hedged sentence

0.0510

closest p · 1.0× alpha

0.0510

boldest claim

The sentences

borderline significancep = 0.0510so close (0.05 < p ≤ 0.1)

Although the cohort as a whole had a high incidence of delayed nausea (37.72%), the 3 antiemetics group had less delayed nausea (33.18%) than the 2 antiemetics group (42.25%), with borderline significance ( p = 0.0510).

also in 7,017 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.